AEM 28

Drug Profile

AEM 28

Alternative Names: AEM-28; Apolipoprotein E mimetic

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Alabama at Birmingham
  • Developer LipimetiX Development
  • Class Antihyperlipidaemics; Apolipoprotein therapeutics; Peptides
  • Mechanism of Action Apolipoprotein B modulators; Apolipoprotein E agonists; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type IIa
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

  • 07 May 2018 AEM 28 licensed to Anji Pharma in China, Taiwan and Hong Kong
  • 26 Aug 2016 AEM 28 is available for licensing as of 29 Jul 2016. http://www.lipimetix.com/businessmodel.html
  • 25 Aug 2016 Phase-II development is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top